Prostate cancer patients could avoid chemotherapy with new blood test

A new development in the testing of one of Australia’s biggest cancer killers, prostate cancer, could help avoid unncessary chemotherapy and improve the treatment of patients.

Sydney researchers have developed a blood test which can track a patient’s progress to avoid them being exposed to long stints of chemotherapy which can carry side-effects such as fatigue, nausea and diarrhoea.

Currently up to 50 percent of patients with advanced prostate cancer don’t respond to the chemotherapy drug Docetaxel which is given after failed hormone therapy.

Usually patients are given Docetaxel for up to three months before doctors know whether they are responding to treatment.
Dr Kate Mahon said the new blood test could shorten that process by searching for a marker in the blood called mGSTP1.

“It’s an epigenetic blood marker, so it’s a piece of DNA that comes from the prostate cancer cells,” lead investigator Dr Kate Mahon, medical oncologist at Chris O’Brien Lifehouse, said.

Read more at nanoappsmedical.com

Image Credit:     Nine News Sydney

News This Week

Laboratory’s nanopore research hits a nerve

Since the discovery of biological ion channels and their role in physiology, scientists have attempted to create man-made structures that mimic their biological counterparts. New research by Lawrence Livermore National Laboratory (LLNL) scientists and [...]

Gene Therapy Promotes Nerve Regeneration

Researchers from the Netherlands Institute for Neuroscience (NIN) and the Leiden University Medical Center (LUMC) have shown that treatment using gene therapy leads to a faster recovery after nerve damage. By combining a surgical [...]

2018-12-03T06:09:01+00:00

Leave A Comment